Literature DB >> 15337666

Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications.

Douglas L Leslie1, Robert A Rosenheck.   

Abstract

OBJECTIVE: The purpose of the study was to determine the proportion of patients with schizophrenia with a stable regimen of antipsychotic monotherapy who developed diabetes or were hospitalized for ketoacidosis.
METHOD: Patients with schizophrenia for whom a stable regimen of antipsychotic monotherapy was consistently prescribed during any 3-month period between June 1999 and September 2000 and who had no diabetes were followed through September 2001 by using administrative data from the Department of Veterans Affairs. Cox proportional hazards models were developed to identify the characteristics associated with newly diagnosed diabetes and ketoacidosis.
RESULTS: Of the 56,849 patients identified, 4,132 (7.3%) developed diabetes and 88 (0.2%) were hospitalized for ketoacidosis. Diabetes risk was highest for clozapine (hazard ratio=1.57) and olanzapine (hazard ratio=1.15); the diabetes risks for quetiapine (hazard ratio=1.20) and risperidone (hazard ratio=1.01) were not significantly different from that for conventional antipsychotics. The attributable risks of diabetes mellitus associated with atypical antipsychotics were small, ranging from 0.05% (risperidone) to 2.03% (clozapine).
CONCLUSIONS: Although clozapine and olanzapine have greater diabetes risk, the attributable risk of diabetes mellitus with atypical antipsychotics is small.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15337666     DOI: 10.1176/appi.ajp.161.9.1709

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  35 in total

Review 1.  Antipsychotic drugs and diabetes--an application of the Austin Bradford Hill criteria.

Authors:  R I G Holt; R C Peveler
Journal:  Diabetologia       Date:  2006-05-13       Impact factor: 10.122

Review 2.  Rethinking antipsychotic formulary policy.

Authors:  R A Rosenheck; D L Leslie; Susan Busch; Ethan S Rofman; Michael Sernyak
Journal:  Schizophr Bull       Date:  2007-07-18       Impact factor: 9.306

Review 3.  Atypical antipsychotics and diabetic ketoacidosis: a review.

Authors:  Melanie D Guenette; Margaret Hahn; Tony A Cohn; Celine Teo; Gary J Remington
Journal:  Psychopharmacology (Berl)       Date:  2013-01-24       Impact factor: 4.530

4.  Is Metabolic Syndrome On the Radar? Improving Real-Time Detection of Metabolic Syndrome and Physician Response by Computerized Scan of the Electronic Medical Record.

Authors:  Kingwai Lui; Gagandeep Randhawa; Vicken Totten; Adam E Smith; Joachim Raese
Journal:  Prim Care Companion CNS Disord       Date:  2016-01-28

Review 5.  Pharmacologically-induced metabolic acidosis: a review.

Authors:  George Liamis; Haralampos J Milionis; Moses Elisaf
Journal:  Drug Saf       Date:  2010-05-01       Impact factor: 5.606

6.  Type 2 diabetes among persons with schizophrenia and other psychotic disorders in a general population survey.

Authors:  Jaana Suvisaari; Jonna Perälä; Samuli I Saarni; Tommi Härkänen; Sami Pirkola; Matti Joukamaa; Seppo Koskinen; Jouko Lönnqvist; Antti Reunanen
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-04       Impact factor: 5.270

7.  Adverse childhood experiences and prescribed psychotropic medications in adults.

Authors:  Robert F Anda; David W Brown; Vincent J Felitti; J Douglas Bremner; Shanta R Dube; Wayne H Giles
Journal:  Am J Prev Med       Date:  2007-05       Impact factor: 5.043

8.  Cardiometabolic consequences of therapy for chronic schizophrenia using second-generation antipsychotic agents in a medicaid population: clinical and economic evaluation.

Authors:  Alex Ward; Peter Quon; Safiya Abouzaid; Noah Haber; Saed Ahmed; Edward Kim
Journal:  P T       Date:  2013-02

Review 9.  Psychiatric drugs impact mitochondrial function in brain and other tissues.

Authors:  Shawna T Chan; Michael J McCarthy; Marquis P Vawter
Journal:  Schizophr Res       Date:  2019-11-16       Impact factor: 4.939

10.  An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia.

Authors:  Giorgio L Colombo; Mauro Caruggi; Sergio Di Matteo; Alessandro Rossi
Journal:  Neuropsychiatr Dis Treat       Date:  2008-10       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.